Bioventix Plc Siemens Launches New Troponin Test

 
TIDMBVXP 
 
Bioventix plc 
                        ("Bioventix" or "the Company") 
 
                      Siemens Launches New Troponin Test 
 
The Board has become aware of the launch of a new test by Siemens for troponin, 
a key biomarker used in heart attack diagnostics.  This launch is significant 
for Bioventix as the test uses antibodies created by Bioventix and accordingly 
the Company will receive product royalties based on Siemens activities in this 
area.  There is more detailed information on the Siemens web-site: 
 
http://www.siemens.com/press/en/pressrelease/?press=/en/pressrelease/2017/ 
healthineers/pr2017040269hcen.htm&content[]=HC 
 
For further information please contact: 
 
Bioventix plc                                     Tel: [phone] 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: [phone] 
Geoff Nash/Simon Hicks   Corporate Finance 
Stephen Norcross         Corporate Broking 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
The information communicated in this announcement contains inside information 
for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. 
 
 
 
END 
 

(END) Dow Jones Newswires

May 10, 2017 04:00 ET (08:00 GMT)